Anzeige
Mehr »
Donnerstag, 03.07.2025 - Börsentäglich über 12.000 News
Nach dem Genius Act: Dieses börsennotierte XRP-Unternehmen greift im Token-Finanzmarkt an!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
330 Leser
Artikel bewerten:
(1)

Inspirata, Inc.: Inspirata and Fujifilm Strike Commercial Partnership to Supply Digital Pathology Services to the UK National Health Service

Inspirata and Fujifilm Announce a New Commercial Partnership Enabling Fujifilm to Supply and Service Inspirata's Digital Pathology Solutions in the UK.

London, Aug. 01, 2019and radiology enterprise imaging specialists Fujifilmannounced today a commercial partnership which enables Fujifilm to supply and service Inspirata's digital pathology solutions in the United Kingdom.

With increased NHS interest in digital pathology as a vehicle for reducing cancer case turnaround times, caused in part by a chronic shortage in histopathologists, the wholly complementary nature of Inspirata and Fujifilm's respective technologies bridges a technical gap between pathology, radiology and oncology, facilitating a more joined-up and longitudinal approach to patient care.

"Fujifilm's expertise in advanced IT solutions and service delivery is exceptional," details Inspirata EVP and co-founder, Dr Mark Lloyd. "Their experienced team have a proven record of delivering, implementing and servicing national healthcare IT solutions and represent the perfect partner for Inspirata as we respond to ever-increasing UK demand for our digital pathology and cancer informatic services."


With both organisations having proactively embraced an 'open' or 'vendor-neutral' approach to supporting their customers, the Inspirata and Fujifilm partnership is one borne out of a shared commitment to providing NHS trusts with the freedom and flexibility to utilise only the technologies which are right for them. In addition to affording genuine choice in both how and with whom NHS trusts can transition to digital pathology, this partnership also provides Inspirata customers with the option to utilise Fujifilm's award-winning vendor-neutral archive, while simultaneously enhancing Inspirata's current DICOM capabilities should this file format prove itself sufficiently robust as a universal standard for digital pathology.

"This partnership makes great business sense as it enables both Inspirata and Fujifilm to focus 100% on their respective core competencies without fear of becoming overstretched by trying to be all things, to all people," explains Inspirata's European GM, Tim Wing. "However, in blending the digital pathology expertise of Inspirata, with the advanced IT solutions and experience of large-scale implementation of Fujifilm, and both organisations' relentless focus on openness and empowering Trusts in their choice of hardware, it is very evident that the real beneficiaries are going to be our shared UK customers and ultimately NHS patients."

"In deciding to provide digital pathology services in the UK our evaluation of potential partners focussed on two important criteria," explains Kevin Shah, Head of Enterprise New Business, Fujifilm Europe."First, the partner had to offer an innovative, best-in-class technology complete with unparalleled subject matter expertise. Secondly, it was imperative that they share the commitment to openness and vendor neutrality for which we have become synonymous. Inspirata deliver on both counts and as such our combined partnership will see us deliver a truly unique solution to the UK market."


About Inspirata Europe


Inspirata Europe Limited helps patients fighting cancer-and the clinicians they trust-to make every moment matter. Our comprehensive cancer informatics solutions bring disparate data together throughout the entire cancer care journey to drive informed decisions that improve survivorship.Inspirata has assembled the most advanced and proven technologies to address the complex challenges of delivering cancer care and conducting ground-breaking research. We combine leading digital pathology solutions with automated cancer registry solutions, comprehensive cancer informatics and advanced patient engagement tools to bring users the broadest oncology informatics platform available globally. For more information, please visit www.inspirata.comor contact info@inspirata.com.

About FUJIFILM UK

FUJIFILM UK Ltd Medical Systems is a leading provider of diagnostic imaging products and medical informatics solutions that meet the evolving needs of healthcare facilities both today and tomorrow. Offering a range of digital X-ray systems including detectors, mobiles, and rooms, to the comprehensive SYNAPSE Enterprise Imaging portfolio, to full-field digital mammography systems with digital breast tomosynthesis, high quality, technologically advanced endoscopic imaging solutions and devices and computed tomography solutions, Fujifilm has products that are ideal for any size imaging environment. Fujifilm's TeraMedica Division, the leading provider of vendor neutral, enterprise-wide solutions.

Attachment

  • Pathologist Workstation_Her2 (https://ml.globenewswire.com/Resource/Download/d117a691-47fe-4f70-b2f2-79b6b412c13d)
© 2019 GlobeNewswire (Europe)
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.